Business · 28/05/1996
FDA Extends Comment Period for Draft Document on Cord Blood Stem Cell Products
The FDA is extending the comment period for a draft document on regulating cord blood stem cell products until July 26, 1996, in response to public requests for additional time to provide written comments.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →